



# Central Nervous System Disease Programs

Indication	Program	Preclinical	IND	Phase 1	Phase 2	Phase 3	NDA/BLA	Commercial	Brii Rights	Partners
PPD	BRII-296								Global	Internally discovered
Anxiety & Depressive Disorder	BRII-297								Global	Internally discovered

\* Greater China – Mainland China, Macau, Hong Kong and Taiwan

(1) The Phase 2 combination clinical trials conducted by Brii:

- BRII-179 / PEG-IFNα
- BRII-179 / BRII-835
- BRII-835 ± PEG-IFNα

(2) Elebsiran was previously known as VIR-2218.

(3) Tobeivart was previously known as VIR-3434. The Phase 2 clinical trials have been conducted by VIR.

(4) VBI launched PreHevbrio/PreHevbri in the United States, Canada, European Union, European Economic Area, the United Kingdom, and Israel. Brii acquired exclusive rights for APAC countries (ex-Japan) in July 2023.

(5) To this date, the development and clinical trials have been conducted by AN2.

## Board of Directors

	Audit and Risk Committee	Nomination Committee	Remuneration Committee	Strategic Committee	Executive Directors	Non-executive Directors	Independent Non-executive Directors
Dr. Zhi Hong							
Dr. Ankang Li							
Dr. Martin J. Murphy Jr.							
Ms. Grace Hui Tang							
Mr. Yiu Wa Alec Tsui							
Mr. Gregg Huber Alton							
Dr. Taiyin Yang							

Chairperson Member

[CVs of the Board Members](#)

## Corporate Executive Team





**Susannah Cantrell, Ph.D.**

Chief Business Officer



**Eleanor (Ellee) de Groot, Ph.D.**

Chief Technology Officer



**Zhi Hong, Ph.D.**

Executive Director  
Chairman of the Board and  
Chief Executive Officer



**Brian Alvin Johns, Ph.D.**

Chief Scientific Officer



**Ankang Li, Ph.D., J.D., CFA**

Executive Director, Chief  
Strategy and Financial Officer  
Chief Executive Officer of TSB  
Therapeutics



**David Margolis, M.D., MPH**

Chief Medical Officer



**Karen D. Neuendorff**

Chief People Officer and Head  
of Human Resources



**Qing Zhu, Ph.D.**

Head of China R&D


[CVs of the Corporate Executive Team Members](#)

## Financial Highlights


<b>BRII-B (RMB'000)</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
<b>Operating Results</b>			
Other income	99,032	107,857	163,728
Other gains and losses	45,062	(12,289)	252,402
Research and development expenses	(494,615)	(440,634)	(402,705)
Administrative expenses	(208,404)	(168,629)	(196,499)
Fair value loss on financial liabilities at FVTPL	(3,598,847)	-	-
Finance costs	(1,175)	(851)	(494)
Listing expenses	(32,137)	-	-
Loss for the year	(4,191,084)	(489,781)	(184,370)
<b>Financial Position</b>			
Total assets	3,611,699	3,391,849	3,198,251

Total liabilities	300,443	234,352	125,869
Total equity (deficits)	3,311,256	3,157,497	3,072,382
<b>Selected Items from Consolidated Cash Flow Statement</b>			
Net cash used in operating activities	(879,457)	(496,279)	(594,014)
Net cash used in investing activities	(475,756)	(1,433,168)	(104,350)
Net cash from financing activities	3,230,134	(3,042)	(10,977)
Net increase in cash and cash equivalents	1,874,921	(1,932,489)	(709,341)
Cash and cash equivalents at end of the year	2,855,093	1,190,572	489,650
<b>Key indicators</b>			
Loss per share - Basic and diluted (RMB)	(9.48)	(0.67)	(0.24)
Current Ratio	1.22	1.34	2.21


#### Research and Development Expenses



#### Total Assets



#### Total Liabilities



#### Brii Biosciences Limited

##### U.S. OFFICES

**Durham, NC, United States**  
WeWork, Suite 05-110, One City Center, 110  
Corcoran Street, Durham, NC 27701, United States

**San Mateo, CA, United States**  
WeWork, Suite 02-114, 1825 South Grant Street, San  
Mateo, CA 94402, United States

Email: [ir@briibio.com](mailto:ir@briibio.com)

##### CHINA OFFICES

**Beijing, China**  
3rd Floor, Building #7, Zhongguancun, Dongsheng  
International Science Park, No. 1 North  
Yongtaizhuang Road, Haidian District, Beijing  
100192, P.R.China

**Shanghai, China**  
Room 805, 8th Floor, Kerry Parkside, No.1155  
Fangdian Road, Pudong, District, Shanghai 201204,  
P.R.China



Supplied by © EUROLAND IR®  
For terms of use and data vendors information,  
see [Disclaimer](#) | [Cookie policy](#)